Literature DB >> 18209093

Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.

Lucie Baudino1, Falk Nimmerjahn, Samareh Azeredo da Silveira, Eduardo Martinez-Soria, Takashi Saito, Michael Carroll, Jeffrey V Ravetch, J Sjef Verbeek, Shozo Izui.   

Abstract

Murine phagocytes express three different activating IgG FcgammaR: FcgammaRI is specific for IgG2a; FcgammaRIII for IgG1, IgG2a, and IgG2b; and FcgammaRIV for IgG2a and IgG2b. Although the role of FcgammaRIII in IgG1 and IgG2a anti-RBC-induced autoimmune hemolytic anemia (AIHA) is well documented, the contribution of FcgammaRI and FcgammaRIV to the development of IgG2a- and IgG2b-induced anemia has not yet been defined. In the present study, using mice deficient in FcgammaRI, FcgammaRIII, and C3, in combination with an FcgammaRIV-blocking mAb, we assessed the respective roles of these three FcgammaR in the development of mild and severe AIHA induced by two different doses (50 and 200 microg) of the IgG2a and IgG2b subclasses of the 34-3C anti-RBC monoclonal autoantibody. We observed that the development of mild anemia induced by a low dose of 34-3C IgG2a autoantibody was highly dependent on FcgammaRIII, while FcgammaRI and FcgammaRIV additionally contributed to the development of severe anemia induced by a high dose of this subclass. In contrast, the development of both mild and severe anemia induced by 34-3C IgG2b was dependent on FcgammaRIII and FcgammaRIV. Our results indicate differential roles of the three activating FcgammaR in IgG2a- and IgG2b-mediated AIHA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209093     DOI: 10.4049/jimmunol.180.3.1948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Authors:  Roudaina Nasser; Mireia Pelegrin; Henri-Alexandre Michaud; Marc Plays; Marc Piechaczyk; Laurent Gros
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 2.  L2pB1: a new player in autoimmunity.

Authors:  Xuemei Zhong; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2010-12-31       Impact factor: 4.407

3.  FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.

Authors:  Falk Nimmerjahn; Anja Lux; Heike Albert; Melissa Woigk; Christian Lehmann; Diana Dudziak; Patrick Smith; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

4.  Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.

Authors:  Angela Giorgini; Heather J Brown; Helen R Lock; Falk Nimmerjahn; Jeffrey V Ravetch; J Sjef Verbeek; Steven H Sacks; Michael G Robson
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

5.  The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis.

Authors:  Maria Allhorn; Juana G Briceño; Lucie Baudino; Christian Lood; Martin L Olsson; Shozo Izui; Mattias Collin
Journal:  Blood       Date:  2010-03-31       Impact factor: 22.113

6.  Fcγ receptor III and Fcγ receptor IV on macrophages drive autoimmune valvular carditis in mice.

Authors:  Patricia M Hobday; Jennifer L Auger; Gregory R Schuneman; Stefanie Haasken; J Sjef Verbeek; Bryce A Binstadt
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

Review 7.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

8.  Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII.

Authors:  Corey D Clay; Richard T Strait; Ashley Mahler; Marat V Khodoun; Fred D Finkelman
Journal:  J Allergy Clin Immunol       Date:  2017-06-15       Impact factor: 10.793

9.  In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

Authors:  Heike Albert; Mattias Collin; Diana Dudziak; Jeffrey V Ravetch; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

10.  Irregular antibodies in no hemolytic autoimmune diseases are able to induce erythrophagocytosis.

Authors:  Paola Ester López-Díaz; María Del Rocío Ruiz-Olivera; Luis Alberto Hernández-Osorio; Jaime Vargas-Arzola; Xareni Valle-Jiménez; Sergio Roberto Aguilar-Ruiz; Honorio Torres-Aguilar
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.